Rectal cancer management: a team sport
The role of radiology and the multidisciplinary conference

W. Donald Buie MD MSc FRCSC
Professor of Surgery and Oncology
Department of Surgery
University of Calgary
Disclosures

• I have no disclosures
Outline

• Background

• Role of radiology in rectal cancer care
  • MRI
  • ERUS

• Multidisciplinary Conference
Coming together is a beginning
Keeping together is progress
Working together is success

Henry Ford
Courtesy of Dr. Robert Madoff, U of Minnesota
Rectal Cancer Care

Multidisciplinary

Interdisciplinary

Multidisciplinary conference
Rectal Cancer Care

Problem:

Variable practice
Variable reporting

Variable outcomes
Local regional staging

• Improve outcomes by standardizing practice and standardizing reporting

• MRI
  • All rectal cancers should get an MRI
  • All rectal MRIs should use a standardized report

• ERUS
  • ERUS should be used for early lesions prior to local excision
MRI is essential for planning optimal treatment for rectal cancer

- Identification of CRM (negative, at risk, positive)
- Relationship of tumour to levators and sphincter complex
- Identification of locally confined tumour for primary surgery
- Identification of locally advanced requiring neoadjuvant therapy
  - Extrarectal involvement T3, T4
  - Extramural vessel invasion (EMVI)
  - Nodal disease
- Assessment of response to neoadjuvant therapy
- Planning low rectal cancer surgery (dissection planes, reconstruction)
Circumferential resection margin (CRM)

- Surgically created plane produced during the dissection of the mesorectum from the surrounding tissues

Importance

- A positive CRM is an independent predictor of local recurrence and survival (Quirke, Adam)
- Risk for positive CRM increases with more advanced T and N stage (Nategaal/Quirke)
- Risk for positive CRM increases with violation of the mesorectum (Quirke)
CRM+ is associated with increased local recurrence

Quirke, Nagtegal, J Clin Oncol 2008;26:303-12
CRM+ is associated with poorer survival

Quirke, Nagtegaal, J Clin Oncol 2008;26:303-12
Prediction of involved CRM

Beets-Tan 2004
MRI is most accurate for CRM
Case #1 Good risk tumour

• A 65 year old male presents with bright red rectal bleeding for 6 months. Comorbidities include hypertension. Colonoscopy demonstrates a large anterior polypoid tumour at 5 cm. CT scan does not demonstrate any metastases and MRI was ordered.
Case # 2

• 56 year old male
• 3-5 months history of altering bowel habits
• Circumferential rectal tumor 2-3 cm above the dentate; ≈6 cm from verge
• CT no mets, incidental finding of liver cirrhosis
Do all T3s need to be treated with neoadjuvant therapy?

Can we save function without compromising cure?
T2 Low Rectal Tumor

Preservation of the T2 hypointense outer muscularis propria wall layer = T2 disease
T2 or early T3?
pT3a (< 5mm invasion) tumours have a good 5 year survival

Merkel et al IJCR Dis 2001;16:298-304
Minimally invasive T3 without extramural vascular invasion (EMVI)

• T2 and T3 tumour < 5 mm without EMVI have an 85-90% 5 yr cancer specific survival

• Mercury trial suggests that MRI can reliably identify EMVI preoperatively

• At the present time these patient should be discussed at Multidisciplinary Tumour Conference prior to a decision to omit neoadjuvant therapy
cT4 invading the levator ani and the sphincter
Does MRI usage affect the uptake of neoadjuvant therapy?
Use of Neoadjuvant chemoradiation/radiation in locally advanced rectal cancer Alberta (2015)

- 325 patients radical resection for rectal cancer; complete data in 321

- MRI obtained in 246 (76.6%); 170 were classified as Stage II or III*  
  - 135 (79.4%) received nCRT (114) or nRT (21)  
  - 35 (20.6%) did not receive  
    - 19 (54%) patient factors, 3 (8.6%) system factors 13 (37%) unknown

*A large proportion of patients who did not receive nCRT/RT did so because of patient factors

*20 (8%) were understaged
Use of Neoadjuvant chemoradiation in locally advanced rectal cancer
Alberta (2015)

• No MRI in 75 (23.4%) patients;
  • 15 (20%) tumours above peritoneal reflection
  • 8 (13.3%) of the remaining 60 received neoadjuvant treatment
  • 26 (43.3%) were stage II or III on final pathology; should have been offered/received nCRT/nRT

• A significant proportion of those that did not get properly staged missed out on neoadjuvant therapy
Measuring the response to neoadjuvant therapy

<table>
<thead>
<tr>
<th>mrTRG</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Tumor bed with low signal intensity signaling fibrosis with no residual intermediate tumor signal</td>
</tr>
<tr>
<td>2</td>
<td>Tumor bed with predominance of fibrosis with minimal residual intermediate tumor signal</td>
</tr>
<tr>
<td>3</td>
<td>Substantial intermediate intensity tumor signal present, but does not predominate over low intensity fibrosis</td>
</tr>
<tr>
<td>4</td>
<td>Minimal fibrosis</td>
</tr>
<tr>
<td>5</td>
<td>No change from baseline</td>
</tr>
</tbody>
</table>

Table 30-3. MRI tumor regression grade (mrTRG) [54]
A. Complete response
B. Equivocal response
C. Residual tumour
D. Smooth scar
E. Small ulcer
F. Residual tumour

What are the limitations of MRI?

• Technique dependent planning; reader dependent

• Susceptible to motion artifact

• Nodal status based on size homogeneity, shape
  • Micro-metastases may be missed

• T2 T3 interface sometimes difficult (experienced radiologist, good rapport)

• Contraindicated in patients with some cardiac pacemakers, orthopedic hardware
Synoptic reporting of MRI

• Improves completeness of reporting
• Ensures that all important information required for decisions is gathered

Alberta
• Provincial plan for synoptic reporting for all rectal MRI
• Standardizing technique as much as possible
• Standardized outcome measures
• Provide feedback to radiologists based on pathologic evaluation
## Synoptic report

**APPENDIX A: MRI SYNOPTIC REPORT**

*Cancer Care Ontario*

**Action Cancer Ontario**

This document was developed by Dr. Danai Alkilali, Laurent Marcelet, Mark Fearman, Gena Brown, Selma Schomaker and Dorothea Tompkins for the CancerCare Ontario Innovation Partnership – a partnership of Cancer Care Ontario and the Canadian Cancer Society.

### 1. MRI PROTOCOL

<table>
<thead>
<tr>
<th>Overall image quality</th>
<th>Adequate</th>
<th>Suboptimal</th>
<th>Non-diagnostic</th>
</tr>
</thead>
</table>

### 2. TUMOUR LOCATION

- Tumour location (from anal verge):
  - Low (0-5.0 cm)
  - Mid (5.1-10.0 cm)
  - High (10.1-15.0 cm)

- Distance of the lowest extent of tumour from anal verge: ______ cm

### 3. TUMOUR CHARACTERISTICS

- Circumferential extent/location (clock face): ________

### 4. T-CATEGORY

- T-category: ________
  - T1 or T2
  - T3
  - T4

- Histological grade: ________
- Vascular invasion: ________

### 5. DISTANCE TO THE MRF AND EXTRAMURAL DEPTH OF INVASION (EMDI)

- Shortest distance of the definitive tumour border to the MRF = ______ mm

- Extramural depth of invasion (EMDI) at this level = ______ mm

- Distance of lowest extent of tumour from top of the anal sphincter: ______ cm

### 6. EXTRAMURAL VASCULAR INVASION (EMVI)

- EMVI: ________
  - Absent
  - Echovascular
  - Present

### 7. MALIGNANT ANEURYSMS AND TUMOUR DEPOSITS

- Any suspicious mesenteric lymph node(s) and/or tumour deposits? ________

### 8. PREVIOUS AND/or CURRENT THERAPIES

<table>
<thead>
<tr>
<th>Radiotherapy</th>
<th>Chemotherapy</th>
<th>Other</th>
<th>Medical treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>________</td>
<td>________</td>
<td>________</td>
<td>________</td>
</tr>
</tbody>
</table>

### 9. FREE TEXT/ADDITIONAL COMMENTS

*For low rectal tumours (0 - 5 cm) only:

Is the lower extent of the tumour at or below the top border of the puborectalis? ________

*If yes, please complete the following section for the most penetrating component of the tumour below the top border of puborectalis:

- Possible component to the submucosa, no definite involvement of internal sphincter (assessed T1)
- Continued to the internal sphincter; no involvement of intersphincter, deltoid or external sphincter (grade 2)
- Through the internal sphincter and intersphincterific fascia or possible or definite involvement of the external sphincter (assessed T3)
- Through the external sphincter and into surrounding soft tissue; no organ involvement (T3a)
- Through external sphincter and possible involvement of adjacent organs (i.e., prostate, vagina) (T4a)
- Through external sphincter and definite involvement of adjacent organs (i.e., prostate, vagina) (T4b)

*If yes, please provide specific location (free text).
Use of preoperative staging MRI has increased from 53% to 67% to 75%
MRI - Meticulous attention to technique (Mercury trial)

- MR definitive sequence
  - high resolution
  - small FOV
  - 3 mm thick non fat suppressed T2 sections
  - orthogonal to lumen and no gap.
- Failure to image perpendicular to lumen attributed to 11/22 overestimation errors on review of data.
- All 18 interpreting GI radiologists went to workshops on technique and reporting.
There are no publications demonstrating superiority of Endorectal in staging.
Endorectal Ultrasound
ERUS Useful for staging prior to local excision

- **Advantages**
  - Simple to perform
  - Inexpensive compared to MRI
  - Accurate for T stage not for N stage

- **Disadvantages**
  - Inaccurate with obstructing lesions
  - Operator dependent
  - Experience dependent
  - Better with staging locally advanced lesions

- Prior to local excision I will obtain an MRI and an ERUS
# ERUS accuracy

## Table 27-1. ERUS accuracy compared to histological stage.

Meta-analysis of 42 studies, N=5039 patients

<table>
<thead>
<tr>
<th>T stage</th>
<th>Pooled sensitivity</th>
<th>Pooled specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td>T1</td>
<td>87.8 % (95 % CI 85.3–90.0 %)</td>
<td>98.3 % (95 % CI 97.8–98.7 %)</td>
</tr>
<tr>
<td>T2</td>
<td>80.5 % (95 % CI 77.9–82.9 %)</td>
<td>95.6 % (95 % CI 94.9–96.3 %)</td>
</tr>
<tr>
<td>T3</td>
<td>96.4 % (95 % CI 95.4–97.2 %)</td>
<td>90.6 % (95 % CI 89.5–91.7 %)</td>
</tr>
<tr>
<td>T4</td>
<td>95.4 % (95 % CI 92.4–97.5 %)</td>
<td>98 % (95% CI 97.8–98.7 %)</td>
</tr>
</tbody>
</table>


Higher sensitivity for locally advanced cancer 95%
Lower accuracy for detecting T2 tumours compared to T1 T3 T4
ERUS N stage

• N-stage
  • Accuracy ~ 75% (64-83%)
  • Problem areas:
    • Blood vessel vs. lymph node (use Doppler)
    • Overstaging (5-22%) – secondary to inflammation
    • Understaging (2-25%) – nodes too small or beyond the range of the probe
      • 50-75% of +’ve nodes are normal size (<5mm)
Overstaging and understaging...

- UK study, multicenter
  - 91 T1 cancers
  - Understaged as T0 – 24%
  - Correctly staged as T1 - 57%
  - Overstaged as T2 - 16%, and as T3 in 2%

Ashraf et.al. Colorectal Disease.2012;14:821-826
Summary: Role of Radiology

• Treatment planning depends on accurate preoperative staging

• Accurate staging predicts surgical and pathologic findings

• MRI plays a central role in assessing response to neoadjuvant therapy

• Quality reporting is essential
Multidisciplinary Conference (MDC)
Rectal Cancer Care

Multidisciplinary

Interdisciplinary

Multidisciplinary conference
Advantages of Multidisciplinary conference (MDC)

• Multidisciplinary team management is associated with
  • improved clinical decision making
  • Superior outcomes
  • Better patient experience
• Improved communication
  • More timely
• Consensus decisions
  • Multiple viewpoints; ownership
• Education – from other specialties (i.e.)
  • MRI
  • Surgical margins
  • Tumour location
  • Chemoradiation risk and benefit for the individual
Structure, Membership of MDC

• Structure
  • Meeting time that everyone can attend
    • Thursday at 4:30 pm TBCC/FMC
    • Cases are identified in advance and sent out on a locked email to the members
    • Radiology and pathology are notified of the cases for review in advance
    • The essential specialty must be represented for a case to be discussed (i.e. if the question is primarily surgical then at least one surgeon must be present)
  
• Membership
  • Surgeons (CR SO HPB), med oncologists, rad oncologists, radiologists, pathologists (case specific)
  • Open to physicians and surgeons from Calgary, Lethbridge, Medicine Hat and Red Deer
  • Attendance credit for MAINPORT
MDC Process

• Chair is at TBCC/FMC
• All other sites are linked by Telehealth
• Individuals can attend by phone
• Case presented by the primary physician/surgeon
• Films are reviewed by radiology
• Discussion regarding question at hand
• Consensus is reached
• Treatment plan set; consults are booked (surgery, chemo, rads)
• Report is generated immediately and distributed the next day to the physicians and surgeons involved with the case
Referral

• Anyone who participates in rectal cancer care can refer a patient to MDC for discussion

• Appropriate referrals:
  • Re-reading MRI and other modalities
  • Surgical management
  • Organizing a second opinion (surgical or medical)
  • Use of neoadjuvant therapy; SCRT vs LCCRT
  • Use of adjuvant chemotherapy
  • Recurrent disease – treatment or palliation
  • Assessment for enrollment in current trials

• Our goal is to have all rectal cancer cases discussed
The Value of Multidisciplinary Teams (Mercury study)

- Rectal cancer MDT
- 2% (4/182) CRM positive rate in resected patients discussed at MDT
- 8% (16/194) CRM positive rate in all discussed patients including unresectable disease
- 28% (16/162) CRM positive rate in patients not discussed
- CRM positive rate in all cases discussed by MDT was significantly lower than in cases not discussed (p<0.001)

Burton et al. Br J Cancer 2006;94:351-57

Following this paper the Royal Marsden Hospital made MDT and MRI mandatory for all rectal cancers
There was a reduction of the overall CRM+ to 3%!!
Team effort
Summary

- Cross sectional imaging is an essential component of comprehensive care of rectal cancer patients

- Accurate local regional staging guides treatment decision
  - MRI should be performed for all rectal cancers
  - ERUS prior to local excision

- MDC is essential to support multidisciplinary and interdisciplinary care
  - It is the foundation for good decision making and excellent comprehensive care